Derek DiRocco - 19 Feb 2026 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Reporting relationship: Director
Issuer ticker: MLYS
Reported as of: 19 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Feb 2026, 19:47:02 UTC
Prior SEC filing: 05 Nov 2025
Next SEC filing: 20 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam Levy, Attorney-in-fact

Key filing fact

Derek DiRocco filed Form 4 for Mineralys Therapeutics, Inc. (MLYS) on 20 Feb 2026.

Key facts

This page summarizes Derek DiRocco's Form 4 filing for Mineralys Therapeutics, Inc. (MLYS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 Feb 2026, 19:47.

Change

Previous filing in this sequence was filed on 05 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001792061 Primary reporting owner

DiRocco Derek

Relationship: Director
Address: 150 N. RADNOR CHESTER RD., SUITE F200, RADNOR
Signature: /s/ Adam Levy, Attorney-in-fact
Signature date: 20 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MLYS transaction

Common Stock

Award

Transaction value: $0
Shares: +6,200
Change %
Price: $0.000000
Shares after: 6,200
Date: 19 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MLYS transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +8,300
Change %
Price: $0.000000
Shares after: 8,300
Date: 19 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,300
Exercise price: $28.06
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Restricted Stock Units ("RSUs") are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.

Footnote F2

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the RSUs and options for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon settlement of the RSUs, or exercise of the options, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the RSUs or option and underlying common stock, as applicable.

Footnote F3

The stock option vests in 12 substantially equal monthly installments following the date of grant.